全球小分子 CMO 市場規模（按應用、地區、範圍和預測）

小分子CMO市場規模及預測

2024 年小分子 CMO 市場規模價值 478 億美元，預計到 2031 年將達到 840 億美元，在 2024-2031 年預測期內的複合年增長率為 5.8%。製藥業的成長和對抗癌藥物的需求不斷增加是推動市場成長的主要因素。全球小分子 CMO 市場報告對市場進行了全面的評估。它對關鍵細分市場、趨勢、市場推動因素、阻礙因素、競爭格局以及在市場中發揮關鍵作用的因素進行了全面分析。

定義全球小分子 CMO 市場

CMO 代表合約製造組織。CMO 也稱為合約開發和製造組織 (CDMO)。它是一個以合約方式向製藥業的其他公司提供服務的組織，提供從藥物開發到藥物製造的綜合服務。小分子主要是在實驗室中分離或重新合成的天然化合物。這些可以互換地稱為藥物。大多數藥物都屬於小分子類別。小分子定義明確，且與製造製程無關。

製藥業受到產能短缺和過剩週期的影響，不只是合約製造商如此，內部製造商也是如此。因此，對於合約製造組織（CMO）來說，在產能擴張和合作夥伴選擇方面做出審慎的決定非常重要。CMO 提供的 "一站式服務" 預計將影響其成長，因為它有助於擴大產品組合。大型 CMO 正在順應擴張的趨勢，並專注於生物製藥和藥物開發的細分領域。這些公司專注於建立基因改造產品開發的監管途徑。

全球小分子 CMO 市場概覽

製藥業的成長和對抗癌藥物的需求不斷增加是推動市場成長的主要因素。其他成長因素，如對製程開發 CMO 服務的需求不斷增長、小分子藥物通路強勁、 FDA 批准率不斷上升、併購以及對提供高效 API 的 CDMO 的需求不斷增長，預計也將在不久的將來推動市場成長。

此外，採用外包所帶來的成本和時間節省也有助於推動產業成長。公司正在投資基礎設施、人才和技術，以獲取更大的外包收入佔有率。預計生物製劑專利到期將促使需求增加。此外，在綜合或風險共擔商業模式中提供加值服務的端到端服務提供者的存在也有望推動該產業的發展。

此外，新產品的推出和新的藥物輸送機制預計將推動外包需求。該行業正在經歷產能短缺和過剩的交替循環，不僅是合約製造商如此，內部製造商也同樣如此。因此，對於合約製造組織（CMO）來說，在產能擴張和合作夥伴選擇方面做出審慎的決定非常重要。

然而，目前全球 CMO 的商業模式面臨許多課題和複雜性。市場分散、定價壓力、產量下降、新技術以及早期公司缺乏風險投資 (VC) 資金等因素導致 CMO 支出有可能降至經濟衰退水平以下。

目錄

第1章 全球小分子CMO市場簡介

• 市場概況
• 調查範圍
• 先決條件

第 2 章 執行摘要

第3章 VERIFIED MARKET RESEARCH研究方法

• 數據挖掘
• 驗證
• 一次資料
• 數據源列表

第4章 全球小分子CMO市場展望

• 概述
• 市場動態
  • 促進因素
  • 阻礙因素
  • 機會
• 波特的五力模型
• 價值鏈分析

第5章 全球小分子 CMO 市場（依應用）

• 概述
• 心血管
• 腫瘤
• 糖尿病
• 免疫性疾病

第6章 全球小分子 CMO 市場（按地區）

• 概述
• 北美
  • 美國
  • 加拿大
  • 墨西哥
• 歐洲
  • 德國
  • 英國
  • 法國
  • 歐洲其他地區
• 亞太地區
  • 中國
  • 日本
  • 印度
  • 亞太其他地區
• 世界其他地區
  • 拉丁美洲
  • 中東/非洲

第7章全球小分子CMO市場競爭格局

• 概述
• 各公司市場排名
• 主要發展策略

第8章 公司簡介

• Lonza Group
• Wuxi AppTec Co. Ltd.
• Catalent Inc
• Patheon Inc.
• Cambrex
• SIEGFRID
• WuXi Biologics
• Groupe PCAS

第9章 附錄

第10章 相關報導

Small Molecule CMO Market Size And Forecast

Small Molecule CMO Market size was valued at USD 47.8 Billion in 2024 and is projected to reach USD 84.0 Billion by 2031, growing at a CAGR of 5.8% during the forecast period 2024-2031. The growing pharmaceutical industry and rising demand for oncology drugs are the major factors that are driving the growth of the market. The Global Small Molecule CMO Market report provides a holistic evaluation of the market. The report offers a comprehensive analysis of key segments, trends, drivers, restraints, competitive landscape, and factors that are playing a substantial role in the market.

Global Small Molecule CMO Market Definition

CMO states contract manufacturing organization. CMO is also called contract development and manufacturing organization (CDMO). It is an organization that serves other companies in the pharmaceutical industry on a contract basis to make available comprehensive services from drug development through drug manufacturing. completion of projects and subsequent regulatory submission. Small molecules are primarily made up of naturally occurring compounds that have been isolated or re-synthesized in the laboratory. These are interchangeably called drugs. The majority of drugs have come under the category of small molecules. Small molecules are well defined and independent of the manufacturing process.

The industry has been alternating between the cycles of inadequate and excessive production capacity for the contract as well as captive manufacturers. Hence, it is important for Contract Manufacturing Organizations (CMOs) to make cautious decisions pertaining to capacity expansion and choice of deals. One-stop-shop" offered by the CMO's for the promotion of a portfolio of a complete range of products is anticipated to influence the growth of CMO's. The larger CMOs are embracing the trend of moving and focusing on the niche areas of biopharmaceutical and pharmaceutical development. They are focusing on the establishment of regulatory pathways for transgenic-based product development.

What's inside a VMR industry report?

Our reports include actionable data and forward-looking analysis that help you craft pitches, create business plans, build presentations and write proposals.

Global Small Molecule CMO Market Overview

The growing pharmaceutical industry and rising demand for oncology drugs are the major factors that are driving the growth of the market. Other growth drivers such as growing demand for process development CMO services, robust pipeline of small molecule drugs & increasing rate of FDA approvals, mergers & acquisitions, growing demand for CDMOs offering highly potent API etc. are expected to boost the growth of the market in the near future.

In addition, Cost saving and time-saving benefits associated with the implementation of outsourcing is responsible for driving industrial growth. Companies are investing in infrastructure, personnel, and technology in order to gain a significant share of the outsourcing revenue. Increasing demand as a consequence of the ongoing patent cliff of the biologic drugs is expected to fuel demand. Furthermore, the Presence of end-to-end service providers that are engaged in providing value-added services for an integrated or risk-sharing business model is expected to bolster progress in this industry.

Moreover, new product launches and novel drug delivery mechanisms are anticipated to drive outsourcing demand. The industry has been alternating between the cycles of inadequate and excessive production capacity for the contract as well as captive manufacturers. Hence, it is important for Contract Manufacturing Organizations (CMOs) to make cautious decisions pertaining to capacity expansion and choice of deals.

However, there are several challenges and complications allied with the present business model of CMOs globally. The fragmented nature of the market combined with price pressure, lower unit volumes and new technologies and lack of Venture Capitalist (VC) funding for early-stage companies have resulted in less expenditure than precession levels which is likely to pose a threat to CMOs.

Global Small Molecule CMO Market: Segmentation Analysis

The Global Small Molecule CMO Market is Segmented on the basis of Application, and Geography.

Small Molecule CMO Market, By Application

• Cardiovascular
• Oncology
• Diabetes
• Immunological Disorders
• Based on Application, the market is bifurcated into Cardiovascular, Oncology, Diabetes, and Immunological Disorders. Immunological Disorders are likely to register the highest CAGR over the forecast period. API dominated with respect to revenue as a consequence of the rising demand for
• High Potency Active Pharmaceutical Ingredients (HPAPI)
• . Market entities are engaged in the development of large-scale mfg. facilities on the pilot as well as commercial scale.

Small Molecule CMO Market, By Geography

• North America
• Europe
• Asia Pacific
• Latin America
• Rest of the World
• On the basis of regional analysis, The Global Small Molecule CMO Market is classified into North America, Europe, Asia Pacific, and the Rest of the world. North America dominated with respect to revenue share in 2016, however, Asia Pacific is projected to grow at a surplus rate. This growth is supported by rising in the number of companies outsourcing projects in the developing economies of this region. A larger share of the North American region is a consequence of the expansion of the U.S. healthcare industry. This share is anticipated to decrease to a substantial extent thus driving the share of BRIC countries in this sector

Key Players

• The "Global Small Molecule CMO Market" study report will provide a valuable insight with an emphasis on the global market including some of the major players such as
• Lonza Group, Wuxi AppTec Co. Ltd., Catalent Inc, Patheon Inc., Cambrex, SIEGFRID, WuXi Biologics, Groupe PCAS.

Our market analysis also entails a section solely dedicated to such major players wherein our analysts provide an insight into the financial statements of all the major players, along with its product benchmarking and SWOT analysis. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.

Key Developments

• Partnerships, Collaborations and Agreements
• On July 2020, Viatris extended its partnership with Gilead to build COVID-19 treatments by announcing a global agreement with the company to commercial Remdesivir in 127 low- and middle-income countries. The drug was launched under the brand name DESREM in India. Viatris has a long-standing history of partnering with Gilead Sciences to tackle critical public health issues in India and worldwide, beginning with expanding access to high-quality, affordable HIV/AIDS antiretrovirals.
• On June 2021, Eisai Co., Ltd. and Bristol-Myers Squibb Company announced a global strategic partnership agreement to develop and commercialize MORAb-202, an antibody-drug combination. MORAb-202 will be developed and commercialized jointly by Eisai and Bristol Myers Squibb under the terms of the agreement. Eisai would remain responsible for the manufacturing and supply of MORAb-202 globally.
• On August 2021, Cipla Limited and Kemwell Biopharma Private Limited, a biopharmaceutical Contract Development and Manufacturing Organization announced a joint venture agreement to develop, manufacture and commercialize biosimilars for global markets. Under the terms of the agreement, the joint venture would leverage Cipla and Kemwell's complementary strengths for end-to-end product development, clinical development, regulatory filings, manufacturing, and commercialization of biopharmaceutical products.
• Mergers and Acquisitions
• On July 2020, US-based Advent International agreed to acquire a controlling stake in RA Chem Pharma from its parent Micro Labs. Another US-based giant, KKR, also agreed to acquire a 54% stake in JB Chemicals and Pharmaceuticals for USD 611 million.
• Product Launches and Product Expansions
• On December 2020, Viatris sponsored the Panacea event in India and Narayana Health, Ayush Society, to improve focus on mental health improvement in India. It conducts a series of virtual sessions on yoga, stress management, nutrition, and mental health to help patients overcome post-COVID-19 anxiety, fear, and mental trauma. Special sessions were conducted by renowned pulmonologists, neurologists, and cardiologists.

TABLE OF CONTENTS

1. INTRODUCTION OF GLOBAL SMALL MOLECULE CMO MARKET

• 1.1. Overview of the Market
• 1.2. Scope of Report
• 1.3. Assumptions

2. EXECUTIVE SUMMARY

3. RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

• 3.1. Data Mining
• 3.2. Validation
• 3.3. Primary Interviews
• 3.4. List of Data Sources

4. GLOBAL SMALL MOLECULE CMO MARKET OUTLOOK

• 4.1. Overview
• 4.2. Market Dynamics
  • 4.2.1. Drivers
  • 4.2.2. Restraints
  • 4.2.3. Opportunities
• 4.3. Porters Five Force Model
• 4.4. Value Chain Analysis

5. GLOBAL SMALL MOLECULE CMO MARKET, BY APPLICATION

• 5.1. Overview
• 5.2. Cardiovascular
• 5.3. Oncology
• 5.4. Diabetes
• 5.5. Immunological Disorders

6. GLOBAL SMALL MOLECULE CMO MARKET, BY GEOGRAPHY

• 6.1. Overview
• 6.2. North America
  • 6.2.1. U.S.
  • 6.2.2. Canada
  • 6.2.3. Mexico
• 6.3. Europe
  • 6.3.1. Germany
  • 6.3.2. U.K.
  • 6.3.3. France
  • 6.3.4. Rest of Europe
• 6.4. Asia Pacific
  • 6.4.1. China
  • 6.4.2. Japan
  • 6.4.3. India
  • 6.4.4. Rest of Asia Pacific
• 6.5 Rest of the World
  • 6.5.1 Latin America
  • 6.5.2 Middle East & Africa

7. GLOBAL SMALL MOLECULE CMO MARKET COMPETITIVE LANDSCAPE

• 7.1. Overview
• 7.2. Company Market Ranking
• 7.3. Key Development Strategies

8. COMPANY PROFILES

• 8.1. Lonza Group
  • 8.1.1. Overview
  • 8.1.2. Financial Performance
  • 8.1.3. Product Outlook
  • 8.1.4. Key Developments
• 8.2. Wuxi AppTec Co. Ltd.
  • 8.2.1. Overview
  • 8.2.2. Financial Performance
  • 8.2.3. Product Outlook
  • 8.2.4. Key Developments
• 8.3. Catalent Inc
  • 8.3.1. Overview
  • 8.3.2. Financial Performance
  • 8.3.3. Product Outlook
  • 8.3.4. Key Developments
• 8.4. Patheon Inc.
  • 8.4.1. Overview
  • 8.4.2. Financial Performance
  • 8.4.3. Product Outlook
  • 8.4.4. Key Developments
• 8.5. Cambrex
  • 8.5.1. Overview
  • 8.5.2. Financial Performance
  • 8.5.3. Product Outlook
  • 8.5.4. Key Developments
• 8.6. SIEGFRID
  • 8.6.1. Overview
  • 8.6.2. Financial Performance
  • 8.6.3. Product Outlook
  • 8.6.4. Key Developments
• 8.7. WuXi Biologics
  • 8.7.1. Overview
  • 8.7.2. Financial Performance
  • 8.7.3. Product Outlook
  • 8.7.4. Key Developments
• 8.8. Groupe PCAS
  • 8.8.1. Overview
  • 8.8.2. Financial Performance
  • 8.8.3. Product Outlook
  • 8.8.4. Key Developments

9. Appendix

10. Related Reports